Who is sponsoring NCT03341572?

NCT03341572 is sponsored by Jingyuan,Xu.

What drugs are being tested in NCT03341572?

Interventions in NCT03341572: 5,10 and 15cmH2O positive end expiratory pressure.

What condition does NCT03341572 study?

NCT03341572 studies Sepsis, ARDS, Traumatic Brain Injury.

Is NCT03341572 still recruiting?

NCT03341572 is currently status unknown. Last updated 14 November 2017.

Last reviewed 2017-11-14 · How we verify

NCT03341572

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Positive End Expiratory Pressure on Central Venous Pressure Among Patients With Different Lung Compliance

Status unknown NA Last updated 14 November 2017

What this trial tests

NA trial testing 5,10 and 15cmH2O positive end expiratory pressure in Sepsis in 30 participants. Status unknown.

Timeline

13 November 2017

Primary endpoint
30 December 2017

30 December 2017

Quick facts

Lead sponsor	Jingyuan,Xu
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	30
Start date	13 November 2017
Primary completion	30 December 2017
Estimated completion	30 December 2017
Sites	1 location across China

Drugs / interventions tested

5,10 and 15cmH2O positive end expiratory pressure

Conditions studied

Sepsis — all drugs for Sepsis →
ARDS — all drugs for ARDS →
Traumatic Brain Injury — all drugs for Traumatic Brain Injury →

Sponsor

Jingyuan,Xu

Who can join

Adults 18 to 80, any sex, with Sepsis or ARDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To observe the effect of PEEP on CVP among patients with different respiratory compliance

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other Jingyuan,Xu trials

Trials by the same sponsor.

NCT03340649 — The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis · unknown
NCT03296761 — Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03341572 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jingyuan,Xu
Last refreshed: 14 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03341572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing